Neoangiogenesis is essential for tumor development, invasion, and dissemination. The most potent of the cytokines associated with angiogenesis is vascular endothelial growth factor (VEGF). The aim of the present study was to determine VEGF serum level in patients with salivary gland tumor. Using an ELISA kit, the circulating levels of VEGF in sera from 58 patients with salivary gland tumor and 30 healthy controls were assessed. Mean VEGF levels in sera of patients with salivary gland tumors (574.9 ± 414.3) were significantly higher than those in controls (263.9 ± 310.0) ( ). Within the salivary gland tumor group, mean serum VEGF concentration in malignant tumors ( ) was 727.3 ± 441.8？pg/mL, and that in benign tumors ( ) was 442.2 ± 343.3？pg/mL. Mean serum VEGF concentration was significantly higher in malignant tumors than in benign tumors ( ) and was higher in benign tumors than in controls ( ). The data in the present study clearly show that VEGF level was consistently upregulated in benign and malignant tumors in comparison to healthy controls. However, the role of VEGF as a prognostic factor in salivary gland tumor and its application in antiangiogenic therapy require further clinical research. 1. Introduction Neoangiogenesis, the development of new vessels from pre-existing ones, is necessary for tumor development, invasion, and dissemination. Angiogenic process not only delivers nutrients for tumor growth but also increases the chance for tumor cells to enter the circulation and metastasis [1]. A variety of signals such as diminished nutrition or oxygen in tissue or genetic changes in oncogenes or tumor suppressor genes can start angiogenic process. Different factors produced from stromal and tumor cells such as growth factors, cytokines, enzymes, and adhesion molecules are involved in this process, and the most potent of them is vascular endothelial growth factor (VEGF) [2]. Among the VEGF family, which consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-F, VEGF-A is a key angiogenic factor and is mostly used to promote angiogenic phenotype by a tumor [3]. VEGF-A is a dimeric glycoprotein with a molecular weight of 34–45？KDa, consisting of two subunits. Increased VEGF expression was seen in different physiologic and pathologic conditions which was associated with hypoxia [4]. VEGF is expressed in several malignant tumors which indicates its importance in angiogenesis process. Overexpression of VEGF was found in body fluids and solid tumors such as brain, colon, breast, kidney, bladder, lung, and oral cancer [5]. However, no investigations have
References
[1]
S. Pourshahidi, A. A. Tadbir, H. Ebrahimi et al., “Serum level of vascular endothelial growth factor-c in patients with head and neck squamous cell carcinoma,” Australian Journal of Basic and Applied Sciences, vol. 5, no. 9, pp. 426–429, 2011.
[2]
D. Hodorowicz-Zaniewska, W. Kibil, A. Ma？ek, J. Szpor, J. Kulig, and K. Sztefko, “Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients,” Polish Journal of Pathology, vol. 63, no. 4, pp. 255–260, 2012.
[3]
S. Nayak, M. M. Goel, S. Chandra et al., “VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas,” Oral Oncology, vol. 48, no. 3, pp. 233–239, 2012.
[4]
M. Farzin, M. Mardani, J. Ghabanchi et al., “Serum level of matrix metalloproteinase-3 in patients with oral Lichen planus,” Iranian Red Crescent Medical Journal, vol. 14, no. 1, 2012.
[5]
C.-J. Liu, K.-W. Chang, S.-C. Lin, and H.-W. Cheng, “Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma,” Oral Oncology, vol. 45, no. 10, pp. 920–925, 2009.
[6]
D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3, pp. 353–364, 1996.
[7]
M. Sawatsubashi, T. Yamada, N. Fukushima, H. Mizokami, O. Tokunaga, and T. Shin, “Association of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinoma,” Virchows Archiv, vol. 436, no. 3, pp. 243–248, 2000.
[8]
Z.-J. Shang, J.-R. Li, and Z.-B. Li, “Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 1, pp. 17–21, 2007.
[9]
M. E. Baldwin, S. A. Stacker, and M. G. Achen, “Molecular control of lymphangiogenesis,” BioEssays, vol. 24, no. 11, pp. 1030–1040, 2002.
[10]
J. A. Nagy, E. Vasile, D. Feng et al., “Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis,” Journal of Experimental Medicine, vol. 196, no. 11, pp. 1497–1506, 2002.
[11]
J. E. Ohm, D. I. Gabrilovich, G. D. Sempowski et al., “VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression,” Blood, vol. 101, no. 12, pp. 4878–4886, 2003.
[12]
B. Kulapaditharom, V. Boonkitticharoen, and C. Sritara, “Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma,” Journal of Oncology, vol. 2012, Article ID 687934, 7 pages, 2012.
[13]
P. Lequerica-Fernández, A. Astudillo, and J. C. De Vicente, “Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis,” Anticancer Research, vol. 27, no. 5 B, pp. 3661–3666, 2007.
[14]
O. Y. Ke-Xiong, L. Jun, and H. Zhi-Quan, “Association of clinicopathologic parameters with the expression of inducible nitric oxide synthase and vascular endothelial growth factor in mucoepidermoid carcinoma,” Oral Diseases, vol. 17, no. 6, pp. 590–596, 2011.
[15]
L. Hao, N. Xiao-lin, C. Qi, Y. Yi-ping, L. Jia-quan, and L. Yan-ning, “Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma,” International journal of oral science, vol. 2, no. 1, pp. 35–44, 2010.
[16]
W. Swelam, H. Ida-Yonemochi, S. Maruyama, K. Ohshiro, J. Cheng, and T. Saku, “Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma,” Virchows Archiv, vol. 446, no. 6, pp. 653–662, 2005.
[17]
R. T.-P. Poon, S.-T. Fan, and J. Wong, “Clinical implications of circulating angiogenic factors in cancer patients,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1207–1225, 2001.
[18]
Z.-J. Shang, J.-R. Li, and Z.-B. Li, “Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma,” International Journal of Oral and Maxillofacial Surgery, vol. 31, no. 5, pp. 495–498, 2002.
[19]
L. Y. Dirix, P. B. Vermeulen, G. Hubens et al., “Serum basic fibroblst growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer,” Annals of Oncology, vol. 7, no. 8, pp. 843–848, 1996.
[20]
B. Khademi, M. Soleimanpour, A. Ghaderi, and M. Mohammadianpanah, “Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck,” Oral and Maxillofacial Surgery, 2013.
[21]
R. Doi, I. Kuratate, E. Okamoto, K. Ryoke, and H. Ito, “Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas,” Journal of Oral Pathology and Medicine, vol. 28, no. 6, pp. 259–263, 1999.
[22]
P. R. de Faria, R. A. Lima, F. L. Dias et al., “Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behavior,” Journal of Oral Pathology and Medicine, vol. 40, no. 6, pp. 456–459, 2011.
